Cost-utility assessment of amifostine as first-line therapy for ovarian cancer

International Journal of Gynecological Cancer

Volumn 8, Issue 1, 1998, Pages 64-72

  Bennett, C L ^a,b,c,e   Golub, R M ^d   Calhoun, E A ^a,b   Weinstein, J ^c   Fishman, D ^b   Lurain, J ^b   Roland, P ^b   Medio, F ^b   Bukowski, R M ^d  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Health Services Research   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amifostine; Cytoprotection; Ovarian cancer; Utility assessment

Indexed keywords

AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; CELL PROTECTION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; LICENSING; MAJOR CLINICAL STUDY; MEDICAL CARE; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031886899     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Weinstein M, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health 1985; 6: 41-63.
2. Bennett CL, Armitage JL, Buchner D, Gulati S. Economic analysis alongside phase III clinical trials in cancer. Cancer Invest 1994; 12: 336-42.
3. Glasziou P, Mitchell AS. Use of pharmacoeconomic data by regulatory authorities. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott Raven Publishers, 1996; 1141-7.
4. Drummond MF, Davies L. Economic analysis alongside clinical trials: Revisiting the methodologies issues. Int J Technol Assess Health Care 1991; 7: 561-3.
5. Payers PM, Hand DJ. Generalization from phase III clinical trials: Survival, quality of life, and health economics. Lancet 1997; 350: 1025-7.
6. Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers? Cancer 1996; 77: 1854-61.
7. Cancer Facts and Figures - 1997. American Cancer Society, Inc. Atlanta, Georgia.
8. Allen DG, Baak J, Belpomme D, et al. Advanced epithelial ovarian cancer: 1993 consensus statement. Ann Oncol 1994; 4(Suppl.): 83-8.
9. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cis-platin induced toxicities: Results of a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12.
10. Budd GT. Amifostine and chemotherapy-related rhrombocytopenia. Semin Hematol 1996; 23: 49-52.
11. Souetre E, Quing W. Economic analysis of lenogastrim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma. Pharmacol Econ 1994; 6 (Suppl 2): 36-13.
12. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-28.
13. Pauker SG, Kassierer JP. Detection analysis. N Engl J Med 1987; 316: 250-8.
14. Ferguson BM, Keown PA. An introduction to utility measurement in health care. Infect Control Hosp Epidemiol 1995; 16: 240-7.
15. Nord E. Methods for quality adjustment of life years. Soc Sci Med 1992; 34: 560-6.
16. List A, Heaton R, Glinsmann-Gibson B, et al. Amifostine promotes multi-lineage hematopoiesis in patients with myeloplastic syndrome. In: Proceedings of the American Society of Hematology. 1996; 1802a.
17. Buntzel J, Glatzel M, Kottner K, et al. Amifostine provides multi-lineage hematoprotection and protection against non-hematologic toxicities induced by radiochemotherapy. In: Proceedings of the American Society of Hematol. ASH - Orlando, Florida, December 3, 1996; 1781a.
18. Lyman GH, Kudered NM, Green J. The economics of febrile neutropenia. In: Proceedings of the American Society of Hematology. ASH - Orlando, Florida, December 3, 1996; 1374a.
19. Hayman JA, Fairclough DL, Harris JR, Weeks JC. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early stage breast cancer. J Clin Oncol 1997; 15: 1252-60.
20. Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic colony stimulating factors: The American Society of Clinical Oncology Survey. 1996; 14: 2511-18.
21. Lyman GH, Kuderer NM, Balducci L. Thresholds for the use of recombinant human colony stimulating factors based on revised cost estimates incorporating indirect medical, nonmedical, and intangible cost considerations. In: Proceedings of the American Society of Hematology ASH - Orlando, Florida, December 3, 1996; 1373a.